Rosiglitazone in Canada: experience in clinical practice.
BACKGROUND
Type 2 diabetes mellitus is a growing public health concern throughout the world. In North America, most people with type 2 diabetes receive care for their diabetes from a general or family practitioner and so the performance of a new therapeutic agent is best assessed in this setting. The first of a novel new family of oral hypoglycemic agents, rosiglitazone became available in Canada in February 2000.


OBJECTIVE
In this article, we discuss an observational, prospective, cohort, open-label study to assess the clinical efficacy and safety of rosiglitazone in a typical type 2 diabetes population receiving care at a family practice setting with several drug therapies and comorbidities.


CONCLUSIONS
During seven and a half years of experience in our clinical practice, rosiglitazone has been shown as a safe and effective treatment for type 2 diabetics on maximal tolerated or therapeutic doses of metformin and sulfonylurea, in a family practice setting.
Faculty of Medicine, University of Ottawa, CMM- Division of Clinical and Functional Anatomy, 451 Smyth Rd, office # 2162, Ottawa, ON, K1H 8M5, Canada. bpatasi@uottawa.ca
Beata
B
Patasi
Deborah
D
MacNair
Ryan J
RJ
Marble
J Robin
JR
Conway
D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002170:Canada / Q000453:epidemiology; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011446:Prospective Studies; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use
D001786:Blood Glucose; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone